Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PON1 | P27169 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.38 |
| ▸ | NQO2 | P16083 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21116465 | 0.85 | TP53 (0.46) | TP53MAPTSMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL25037449 | 0.80 | MAPT (0.47) | PON1TP53MAPTSMN1; SMN2MTNR1A | |
| SCHEMBL30956065 | 0.78 | KMT2A (0.43) | PON1TP53MAPTSMN1; SMN2NQO2 | |
| SCHEMBL11582560 | 0.77 | ALDH1A1 (0.55) | TP53MAPTSMN1; SMN2CYP2D6THRB | |
| SCHEMBL10222548 | 0.77 | TP53 (0.59) | TP53MAPTSMN1; SMN2MTNR1ATHRB | |
| SCHEMBL13561307 | 0.77 | PON1 (0.41) | PON1MAPT | |
| SCHEMBL2707035 | 0.77 | PON1 (0.41) | PON1MAPTHTR1D | |
| SCHEMBL13462293 | 0.75 | PTPN1 (0.50) | TP53MAPTSMN1; SMN2MTNR1AHTR1A | |
| SCHEMBL2267233 | 0.75 | NPC1 (0.49) | TP53MAPTSMN1; SMN2MTNR1A | |
| SCHEMBL4452486 | 0.75 | PTPN1 (0.50) | TP53MAPTSMN1; SMN2MTNR1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | PON1 3785/4885TP53 2372/4885MAPT 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.